This promotional material is intended for UK Healthcare Professionals experienced in the diagnosis and treatment of psoriasis and psoriatic arthritis. SKYRIZI® (risankizumab) and adalimumab prescribing information & adverse event reporting information can be found below.
UK-RISN-250214. Date of preparation July 2025.
Safety Profile in Psoriasis
Learn more about the safety profile of SKYRIZI in clinical trials and long-term studies for psoriasis and psoriatic arthritis.
*Contraindications include hypersensitivity to the active substance or to any of the excipients and clinically important active infections e.g. active tuberculosis.
Adapted from Papp K, et al. 2023.
AE, adverse event; E, events; MACE, major adverse cardiovascular event; NMSC, nonmelanoma skin cancer; PYs, patient-years; RZB, risankizumab; TEAE, treatment-emergent AE.
aPrimary psoriasis safety pool includes UltIMMa-1, UltMMa-2, IMMhance, IMMvent and NCT0205448110 studies.
b16-week safety data for patients who received RZB 150 mg UltIMMa-1, UltMMa-2, and IMMvent (primary psoriasis safety pool) are included in the 324-week LIMMitless results.
cDue to natural causes (n=1), accident (n=1), cardiovascular event (n=1), cardiac arrest (n=1), sudden cardiac death (n=1), cause unknown (n=2), and COVID-19 infection (n=1); none related to RZB.
dMACE rate in the LIMMitless study is consistent with the incidence rate of MACE in the Psoriasis Longitudinal Assessment and Registry (PSOLAR; 0.57 E/100PY; 95% CI, 0.50–0.65).
eMalignancy types excluding NMSC were colorectal (n=7), skin (n=5), breast (n=4), prostate (n=3), urothelial (n=3), uterine (n=2), brain (n=1), gastric (n=1), and head and neck (n=1).
fSerious hypersensitivity reactions (all of which were considered unrelated to study drug) were paraphenylenediamine allergy (n=1; mild, attributed to hair dye application), generalized microbial eczema (n=1; moderate, attributed to prolonged duration of generalized eczema and lack of response to treatment with hydrocortisone), and Stevens-Johnson syndrome (n=2; severe, attributed to addition of chlorpromazine [n=1] and attributed to addition of Bactrim [n=1]).
gOne nonserious event of ulcerative colitis, considered unrelated to RZB.
Adapted from Strober B. et al. 2019.
aEvents with onset after the first dose of risankizumab until 20 weeks after last dose of risankizumab. E/100PY, events per 100 patient years.
†Deaths were reported as not related to treatment.
Adapted from Warren RB, et al. 2020.
*Defined as AEs occurring with an onset within 20 weeks after the last dose of study drug administration.
AE, adverse event; MACE, major adverse cardiovascular event, NMSC, non-melanoma skin cancer; TEAEs, treatment-emergent adverse events.
Summary of treatment-emergent adverse events with SKYRIZI vs adalimumab in Part A (Weeks 0-16) of the IMMvent Phase III clinical trial1
Randomised controlled trial, intention to treat population (Part A).
aInvestigator assessed AE as possibly related to study drug.
bThe most frequently reported infectious AE were viral upper respiratory tract infection and upper resporatory tract infarction.
cOne patient with acute myocardial infarction on study day 73 (event was not considered to be study grud related by investigator).
dOne patient diagnosed with invasive lobular breast carcinoma on study day 63 following routine mammogram (event was not considered to be study drug related by investigator).
eOne patient with stage IV gall bladder cancer.
fOne patient with cholelithiasis, underwent gall bladder surgery, developed cardiopulmonary arrest and died due to abdominal abscess, sepsis, and gastric perforation (events were not considered to be study drug related by investigator).
AE, adverse event; MACE, major adverse cardiovascular events; NMSC, non-melanoma skin cancer.
Summary of treatment-emergent adverse events with SKYRIZI vs. adalimumab in Part B (Weeks 16-44) of the IMMvent Phase III clinical trial1
Randomised controlled trial. lntention to population (Part B). Patients previously treated with adalimumab, were randomised to receive either adalimumab or SKYRIZI at Week 16.
aInvestigator assessed AE as possibly related to study drug.
bThe most frequently reported Infectious AE were viral upper respiratory tract Infection and upper respiratory tract Infection.
cOne patient with latent tuberculosis. positive TB test during the study.
AE, adverse event; MACE, major adverse cardiovascular events; NMSC, non-melanoma skin cancer.
Safety events from KEEPsAKE 1 and KEEPsAKE 2 through to week 527,8
Adapted from Kristensen LE, et al. 2021.
aSafety reported through data cutoff date (19 April 2021), which includes data through week 52. Data are from any RZB 150-mg group that includes all patients who received RZB 150 mg, including those who started on RZB 150 mg at randomisation and who switched from placebo to RZB 150 mg after week 24.
b10 of the 27 events were cases of COVID-19.
cAn 81-year-old male patient randomised to RZB died of urosepsis on day 96, and a 41-year-old male patient randomised to RZB experienced sudden death on day 502.
E, events; MACE, major adverse cardiovascular events; NMSC, non-melanoma skin cancer; PY, patient-years; RZB, risankizumab; TB, tuberculosis; TEAE, treatment-emergent adverse events.
Featured content
More expert perspectives
View expert perspectives on SKYRIZI’s efficacy data, dosing regimen and safety profile.
UK-RISN-260029. Date of preparation April 2026.
References
- Reich K, et al. Lancet 2019; 394: 576-586.
- Gordon KB, et al. Lancet 2018; 392: 650-661.
- Warren RB, et al. Br J Dermatol 2021; 184: 50-59
- SKYRIZI: Summary of Product Characteristics.
- Strober B, et al. Poster 1714, presented at the 28th European Academy of Dermatology and Venereology (EADV) Congress, 9-13 October 2019, Madrid, Spain
- Papp KA, et al. Am J Clin Dermatol 2025; 26(5): 829–841.
- Kristensen LE, et al. Rheumatology 2023; 62: 2113–2121.
- Östör A, et al. Rheumatology 2023; 62: 2122–2129.
UK-RISN-260045. Date of preparation: May 2026.
